R/R Pancreatic cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Treatment options for recurrent pancreatic cancer are scarce and difficult to administer. In the past, recurrent pancreatic cancer patients were thought to be terminal and rarely lived longer than a year. However, some patients have benefited from more recent therapies that also prioritize managing pain while maintaining nutrition and quality of life. Pancreatic cancer is the 7th most common cancer death and the 11th most common cause of morbidity worldwide. From 7.7 per 100,000 in Europe to 2.2 per 100,000 in Africa, the average age-related incidence rate (ASR) was highly variable. From 0.81 per 100,000 men in India to 15.3 per 100,000 men in Latvia and the Republic of Moldova, the ASR varied by nation. Patients with advanced pancreatic cancer have few options after gemcitabine therapy fails. In patients receiving first-line chemotherapy with gemcitabine, irinotecan monotherapy has been examined. According to Yi et al. reported findings from a phase II trial examining bimonthly doses of irinotecan monotherapy (150 mg/m2) as rescue therapy in this situation.

Description

Recurrent pancreatic cancer is challenging to treat, and there are few effective therapies available. In the past, patients with recurrent pancreatic cancer were thought to be terminal and rarely lived longer than a year. Newer therapies that also prioritize managing pain, nutrition, and quality of life have helped some patients, though. The nerves in the region around the pancreas that are responsible for sensation can be removed to alleviate pain. This is typically carried out during a laparotomy through the skin or by injecting alcohol or other chemicals. Approximately 3% of all cancer cases in the United States, but 7% of all cancer-related deaths, are caused by pancreatic cancer, which is also the eighth most common cancer in women and the tenth most common cancer in men. Pancreatic cancer is becoming more common and fatal, both of which are rising. Despite effective screening techniques, the disease is still difficult to detect, and 80% of cases present at an incurable or incurable stage. Patients with pancreatic cancer frequently have nonspecific laboratory results. On rare occasions, pancreatic cancer can be detected by elevated levels of liver transaminases, bilirubin, and alkaline phosphatase in tests done for other reasons. Advanced pancreatic cancer patients who are underweight and who have nutritional deficiencies (e.g., lower serum albumin or cholesterol levels).

R/R Pancreatic cancer (Epidemiology)

Pancreatic cancer is the 7th most common cause of cancer-related death and the 11th most common cause of morbidity worldwide. The average age-related incidence rate (ASR) varied greatly by region, from 7.7 per 100,000 in Europe to 2.2 per 100,000 in Africa. ASR varied by nation, from 0.81 per 100,000 men in India to 15.3 per 100,000 men in Latvia and the Republic of Moldova. In the United States, 32,970 men and 29,240 women are expected to be diagnosed with pancreatic cancer in the year 2022, according to the American Cancer Society's prediction. Age-adjusted new pancreatic cancer cases increased by 0.5% per year between 2010 and 2019. Between 2015 and 2019, Black men had the highest annual incidence of pancreatic cancer in the United States, at 17.7 per 100,000 people. Pancreatic cancer is rarer in people under the age of 45 when there are no predisposing conditions, such as familial pancreatic cancer and chronic pancreatitis. After age 50, the incidence of pancreatic cancer rises linearly. The average age at diagnosis was 69 years for whites and 65 years for Black people. However, according to some institution-specific data from significant cancer treatment facilities, the average age at diagnosis for both sexes had dropped to 63 years. Although it only makes up about 3% of all cancers in the country, pancreatic cancer is the fourth leading cause of cancer death in both men and women, accounting for 8% of all cancer-related deaths. According to the American Cancer Society, pancreatic cancer will claim the lives of about 47,050 Americans in 2020 (24,640 men and 22,410 women). Whites experienced a slight increase in pancreatic cancer mortality between 2008 and 2017 (0.14% annually), but there were fewer deaths overall. The rate for Black people fell slightly (0.5% annually).

R/R Pancreatic cancer -Current Market Size & Forecast Trends

The market for relapsed or refractory (R/R) pancreatic cancer is projected to grow significantly, with estimates indicating a value of approximately USD 4.34 billion in 2024 and expected to reach around USD 18.7 billion by 2035, reflecting a compound annual growth rate (CAGR) of about 14.2% during this period. The growth is driven by the increasing incidence of pancreatic cancer, advancements in treatment options including chemotherapy, targeted therapies, and immunotherapies, as well as the development of personalized medicine approaches. The market is also benefiting from ongoing research and the introduction of new therapies aimed at improving patient outcomes. As awareness of pancreatic cancer increases and innovative treatment strategies are developed, the R/R pancreatic cancer market is well-positioned for substantial growth through 2035.

Patients with advanced pancreatic cancer have few options if gemcitabine therapy fails. Patients receiving first-line chemotherapy with gemcitabine have had irinotecan monotherapy evaluated. 2009 saw Yi et al. reported findings from a phase II trial examining rescue therapy in this situation with bimonthly doses of irinotecan monotherapy (150 mg/m2). In a phase I study, a brand-new lipid formulation was administered to these patients as a second-line treatment. In both studies, disease control rates (48 vs. 48) were comparable. From 33% in both the Yi and Ko studies to 52% in the current study, more patients had a CA 19-9 reduction of more than 50%. In the trial using liposomal irinotecan, three-month survival was significantly higher (74% vs. compared to early data revealed at the 2011 ASCO GI Cancer Symposium, by 74%. Yi and colleagues claim that. piedze). However, it should be noted that irinotecan's lipid composition appears to be significantly higher 3/4 in terms of toxicity. grade effects. Yi and colleagues conducted this research. This negative outcome was not reported in one study. Since secondary treatment is typically palliative and one of its main objectives is to preserve quality of life, it is important to take this difference in toxicity into account. Prior research has been done on the FOLFIRI regimen for pancreatic cancer patients with gemcitabine resistance. Yu and several others. This phase II study is the first to demonstrate favorable efficacy and toxicity in patients who have previously received gemcitabine. Gerald et al. The regimen should only be used in patients with a good performance status or a good response to first-line therapy, according to a retrospective analysis of 40 patients who received standard FOLFIRI every two weeks after gemcitabine failure. 2009 Neuzilet et al. The research was retrospective as well, and the efficacy results (disease control rate of 50% vs. 44.3% in Gebbia et al.). Newzelette and others. surveys). The estimated median survival in both studies was 6 months, and the majority of toxicities were gastrointestinal and haematological in nature. Nozelts and others. This study is the first to document clinically meaningful efficacy and tolerable toxicities in patients receiving their third and subsequent chemotherapy treatments. Even so, more than 65% of patients received two or more lines of treatment. Neuzilet et al. claim that. Despite similarity in the overall median survival at 6 months, significant variations in results also existed: Gebbia et al. In order, check them. Furthermore, Neazilet et al. If patients receiving the FOLFIRI-1 or FOLFIRI-3 regimens had different outcomes or toxicities, this was not mentioned in the study.

Report Highlights

R/R Pancreatic cancer - Current Market Trends

R/R Pancreatic cancer - Current & Forecasted Cases across the G8 Countries

R/R Pancreatic cancer - Market Opportunities and Sales Potential for Agents

R/R Pancreatic cancer - Patient-based Market Forecast to 2035

R/R Pancreatic cancer - Untapped Business Opportunities

R/R Pancreatic cancer - Product Positioning Vis-a-vis Competitors' Products

R/R Pancreatic cancer - KOLs Insight